HealthEli Lilly says obesity drug combination boosts weight loss in mid-stage trial
Eli Lilly said a combination regimen adding its amylin drug eloralintide to tirzepatide increased weight loss in a closely watched mid-stage trial. The company plans to begin Phase 3 trials of the regimen at the end of the year.
C
CNBC★★☆☆☆2026-09-30 14:15Original
Eli Lilly says obesity drug combination boosts weight loss in mid-stage trial
Health